November 1999
AIDS Patient Care & STDs;Nov99, Vol. 13 Issue 11, p681
Academic Journal
Reports the efficacy of atovaquone suspension in preventing pneumocystis carinii pneumonia in HIV-infected patients. Comparison to aerosolized pentamidine; Treatment in patients intolerant to trimethoprim/sulfonamides; Impact on incidence and mortality.


Related Articles

  • Further Promise with AIDS Drug. Helquist, Michael // Advocate;5/10/88, Issue 498, p38 

    Reports on clinical trials of Imreg-I, an anti-AIDS drug. Drug manufacturer Imreg Inc.'s refusal to release study results to the popular press; Ability of the drug to slow or to prevent the development of pneumocystis pneumonia; Stabilization of anemia common to HIV infection.

  • Pneumocystis carinii pneumonia.  // MMWR: Morbidity & Mortality Weekly Report;6/27/1997 Supplement RR-12, Vol. 46, p4 

    Provides information on the disease pneumocystis carinii pneumonia. Recommendation made by authorities relating to the prevention of exposure to disease; Precautions that should be considered by adolescents, adults and pregnant women.

  • DELAYING THE ONSET OF ILLNESS. Cohan, Gary R. // Advocate;2/8/94, Issue 648, p34 

    Reports that prophylaxis against Pneumocystis carinnii infection may delay the onset of the first AIDS-related illness.

  • Prophylaxis Failure Is Associated with a Specific Pneumocystis carinii Genotype. Hauser, Philippe M.; Sudre, Philippe; Nahimana, Aimable; Francioli, Patrick // Clinical Infectious Diseases;10/1/2001, Vol. 33 Issue 7, p1080 

    To investigate the possible association between Pneumocystis carinii types and various clinical and demographic parameters, we used molecular typing to analyze 93 bronchoalveolar lavage specimens from patients with P. carinii pneumonia (PCP). Multivariate regression analysis revealed an...

  • PCP prophylaxis with use of corticosteroids by neurologists. Kelly, Dearbhla M.; Cronin, Simon // Practical Neurology (BMJ Publishing Group);Apr2014, Vol. 14 Issue 2, p74 

    Pneumocystis jirovecii pneumonia (PCP) is increasingly reported in patients without HIV. Corticosteroids are a major risk factor, with up to 90% of patients receiving corticosteroid treatment prior to the development of PCP. In view of this, many specialties now prescribe PCP prophylaxis to...

  • Prophylaxis and Treatment of Pneumocystis jiroveci Pneumonia in Lymphoma Patients Subjected to Rituximab-Contained Therapy: A Systemic Review and Meta-Analysis. Jiang, Xuqin; Mei, Xiaodong; Feng, Di; Wang, Xiaojing // PLoS ONE;Apr2015, Vol. 10 Issue 4, p1 

    Pneumocystis jiroveci pneumonia (PCP) is frequently reported in lymphoma patients treated with rituximab-contained regimens. There is a trend toward a difference in PCP risk between bi- and tri-weekly regimens. The aims of this systemic review and meta-analysis were to estimate the risk for PCP...

  • Trimetrexate glucoronate associated with anti-Kaposi sarcoma effect. Harris, Pamela Jo // AIDS Patient Care & STDs;Oct96, Vol. 10 Issue 5, p280 

    Reports on a patient with AIDS who developed Pneumocystis carinii pneumonia and Kaposi's sarcoma (KS) and was experimentally given trimetrexate glucoronate. Responses to other treatments; Information on Kaposi's sarcoma and treatment for advanced stages; Regression of KS as a result of...

  • SYTO-13, a Viability Marker as a New Tool to Monitor In Vitro Pharmacodynamic Parameters of Anti-Pneumocystis Drugs. Standaert-Vitse, Annie; Aliouat-Denis, C├ęcile-Marie; Martinez, Anna; Khalife, Sara; Pottier, Muriel; Gantois, Nausicaa; Dei-Cas, Eduardo; Aliouat, El Moukhtar // PLoS ONE;Jun2015, Vol. 10 Issue 6, p1 

    While Pneumocystis pneumonia (PcP) still impacts the AIDS patients, it has a growing importance in immunosuppressed HIV-negative patients. To determine the anti-Pneumocystis therapeutic efficacy of new compounds, animal and in vitro models have been developed. Indeed, well-designed mouse or rat...

  • Pneumocystis carinii Pneumonia Treated with Pyrimethamine and Sulfadiazine. Kirby, Henry B.; Kenamore, Bruce; Guckian, James C. // Annals of Internal Medicine;Oct71, Vol. 75 Issue 4, p505 

    Provides information on a study on the results of pyrimethamine and sulfadiazine therapy in adults with Pneumocystis carinii. Evaluation of the toxicity of the drugs; Patients of different ethnic backgrounds admitted for Pneumocystis carinii pneumonia; Information on antimicrobial agents.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics